HemoBioTech, Inc. (Dallas, TX) has announced that it has been granted a patent for “Methods of Treating Acute Blood Loss.” The treatment described by the patent utilizes the company’s HemoTech solution, which can substitute for red blood cells by carrying oxygen in the blood, and which has been shown to stimulate formation of new red blood cells.
From the press release:
HemoTech is composed of bovine hemoglobin, which is chemically modified with ATP, Adenosine and GSH, to overcome toxicity. HemoTech has been used successfully in an initial clinical study to treat children afflicted with sickle cell anemia, with no apparent side effects. HemoTech stabilizes a cell factor called Hif-1 alpha,
which results in induction of erythropoietin, which stimulates an increase in production of new red blood cells.
HemoTech also has the advantage of delivering oxygen to tissue in the body since it is composed of modified hemoglobin. The combination of delivering oxygen and inducing new red blood cells could be an advantage for treating trauma, elective surgery in third world countries plagued with a high incidence of HIV or Hepatitis contaminated blood and for use by the military and homeland security.
which results in induction of erythropoietin, which stimulates an increase in production of new red blood cells.Press release: HemoBioTech Announces New Patent for Treating Acute Blood Loss…
Product page: HemoTech…